Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience

Affiliations

¹ Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Faculty of Medicine, University of Jordan, Amman, Jordan.
³ Myeloma Section, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁴ Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁵ Myeloma Section, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. salhadidi@uams.edu.

^# Contributed equally.

Bhavesh Mohan Lal et al. Bone Marrow Transplant. 2025 Jul.

. 2025 Jul;60(7):1057-1059.

doi: 10.1038/s41409-025-02607-0. Epub 2025 Apr 17.

¹ Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Faculty of Medicine, University of Jordan, Amman, Jordan.
³ Myeloma Section, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁴ Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
⁵ Myeloma Section, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. salhadidi@uams.edu.

^# Contributed equally.

No abstract available

Conflict of interest statement

Competing interests: SAH reports receiving consulting fees from Jansen and Sanofi.

1. Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives. Onco Targets Ther. 2023;16:441–64. https://doi.org/10.2147/OTT.S370880 . - DOI - PubMed - PMC
1. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705–16. - DOI - PubMed
1. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol J Am Soc Clin Oncol. 2023;41:1265–74. - DOI
1. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol J Am Soc Clin Oncol. 2023;41:2087–97. - DOI
1. Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, et al. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024;205:990–8. https://doi.org/10.1111/bjh.19505 . - DOI - PubMed